Focal radiotherapy improves CAR T cell therapy targeting prostate cancer
Young, C.;Liu, J.;Ren, Y.;Rosa, R.;Hong, H.;Lopez, L.;Buckley, A.;Hao, J.;Yamaguchi, Y.;Park, A.;Christian, L.;Ghimire, H.;Abdelhamid, A.;Zuro, D.;Hui, S.;Martinez, C.;Forman, S.;Li, Y.;Dorff, T.;Murad, J.;Priceman, S.
Show abstract
Chimeric antigen receptor (CAR) T cell therapy has limited efficacy against solid tumors such as prostate cancer due to the immunosuppressive tumor microenvironment (TME). Combining CAR T cells with existing therapies that remodel the TME and promote endogenous immune responses, such as radiation therapy and chemotherapies, may strengthen antitumor responses. Here, we assessed the potency of combining focal radiotherapy (RT), cyclophosphamide (Cy) preconditioning, and prostate stem cell antigen (PSCA)-CAR T cells against syngeneic prostate cancer models. Focal RT alone increased T cell and dendritic cell infiltration and activation in the irradiated tumor. Furthermore, the combination of all three therapies was critical for enhanced antitumor responses and survival across multiple subcutaneous, bone-metastatic, and multifocal disease models. This combination, in the irradiated TME and tumor-draining lymph nodes (tdLN), led to greater antigen presentation by myeloid cells and endogenous T cell activation and cytotoxicity. Our study demonstrates the potency of combining focal RT with PSCA-CAR T cells, significantly improving therapeutic responses in the irradiated tumor and contributing to a more robust systemic immune response against metastatic burden in prostate cancer.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.